Spirit 2

Welcome to the SPIRIT 2 website
 
STI571 Prospective International RandomIsed Trial 2
A phase III, prospective randomised comparison of
  -imatinib (STI571, Glivec/Gleevec) 400mg daily versus
  - dasatinib (Sprycel) 100mg daily
in patients with newly-diagnosed chronic phase chronic myeloid leukaemia


Closed to recruitment : March 2013
Last patient last visit : March 2018